x

Posted 28 February, 2023

Bakhu Holdings, Corp. appointed Dr. Michael R. Hawthorne as new CEO

OTC:BKUH appointed new Chief Executive Officer Dr. Michael R. Hawthorne in a 8-K filed on 28 February, 2023.


  On February 24, 2023, Evripides Drakos resigned as the President and Chief Executive Officer of the Company, in furtherance of the Company's planned restructuring as part of its fundraising efforts, and to facilitate the appointment of Dr. Michael R. Hawthorne as the President and Chief Executive Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Bakhu Holdings, Corp.
Basic Materials/Resources • Gold
Bakhu Holdings Corp. engages in the production, manufacturing, and selling cannabis-related byproducts. It holds a license to plant cell-extraction and replication technology and related proprietary equipment, processes, and formulations of cannabinoids. The company was founded on April 24, 2008 and is headquartered in Long Beach, CA.
Market Cap
$75.3M
View Company Details
Bakhu Holdings, Corp. by TradingView
Relevant filing section
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Departure of President and Chief Executive Officer


On February 24, 2023, Evripides Drakos resigned as the President and Chief Executive Officer of the Company, in furtherance of the Company's planned restructuring as part of its fundraising efforts, and to facilitate the appointment of Dr. Michael R. Hawthorne as the President and Chief Executive Officer of the Company.


Appointment of President and Chief Executive Officer


On February 24, 2023, the Company elected Michael R. Hawthorne, the current Deputy Chief Executive Officer, to serve as the President and Chief Executive Officer of the Company. Mr. Hawthorne does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K, and there is no family relationship between Mr. Hawthorne and any of the Company's other directors or executive officers.


Dr. Hawthorne was appointed our deputy chief executive officer on February 11, 2022. Dr. Hawthorne has served as the executive chairman of Domainex Ltd (Cambridge, UK), a global drug discovery contract research organization, since August 2021 and as an advisor to Closed Loop Medicine Ltd (London, UK) since 2017. Dr. Hawthorne was awarded a Fellowship of The Royal Society of Biology in 2020 in recognition of his contribution to global biosciences. Dr. Hawthorne is an investor and has served as a director of BG Capital (USA) from 2016 to present.


Departure of Director


On February 26, 2023, Moshe Morgenstern tendered his resignation as a member of the Board of Directors of the Company.


Page 2